Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reaffirmed at Citigroup

Citigroup reissued their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report published on Thursday morning,Digital Look reports.

HIK has been the subject of several other reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 195 target price on shares of Hikma Pharmaceuticals in a research report on Monday, June 22nd. Jefferies Financial Group raised their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of GBX 1,687.

Hikma Pharmaceuticals Trading Up 0.3%

Hikma Pharmaceuticals stock opened at GBX 1,499.64 on Thursday. The company has a debt-to-equity ratio of 61.84, a quick ratio of 1.27 and a current ratio of 1.82. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 2,052. The stock has a market cap of £3.16 billion, a P/E ratio of 8.29, a PEG ratio of 2.38 and a beta of 0.65. The firm’s fifty day moving average price is GBX 1,489.23 and its 200-day moving average price is GBX 1,448.39.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.